Moreover, patients with IDH1 wild-type high-grade gliomas harboring BRAF or NF1 mutations and receiving trametinib monotherapy or in combination with dabrafenib had longer progression-free and overall survival than patients who did not receive genotype-matched targeted therapy (20). Here, BRAF is linked to central nervous system cancer.